6 Investor presentation First six months of 2020 COVID-19 negatively impacted new the first half of 2020, but there are US insulin indexed NBRx development US GLP-1 indexed Index 140 13 March, lockdown implemented in most states Insulin Index 140 13 March, implemen 120 120 100 100 84 80 80 60 60 40 1/1F/2e0b 2/1/20 3/1/20 2020 4/1/20 5/1/20 6/1/20 7/J1u/2l 0 2020 40 1/1F/e20b 2/1/20 3/1/20 4/1/2 2020 Note: index based on average weekly observations in January 2020; “Insulin” consists of both long-acting and fast-acting insulin Source: US weekly 1x1 NBRx (Xponent, Diabetes 10 July 2020, Obesity 10 July 2020)
Download PDF file